Please visit the ASCP Itinerary Planner to view the schedule and browse speakers. Registered attendees have access to view the attendee list, view the ePoster gallery and create a personalized schedule. Click HERE for the Itinerary Planner.
The 2017 meeting again included representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Marlene Freeman and John Newcomer with representation of the sectors that are part of the ASCP community led the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, and academia comprised the 2017 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Alan Gelenberg was responsible for review of all program submissions.
2017 ASCP Annual Meeting Submission Deadlines have passed: